GHENT, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results